Profound Medical Corp. PROF
We take great care to ensure that the data presented and summarized in this overview for Profound Medical Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PROF
View all-
Fil LTD Hamilton, D01.89MShares$12.6 Million0.01% of portfolio
-
Gagnon Securities LLC1.73MShares$11.6 Million1.88% of portfolio
-
Letko, Brosseau & Associates Inc Montreal, A8986KShares$6.58 Million0.09% of portfolio
-
Gagnon Advisors, LLC897KShares$5.98 Million3.07% of portfolio
-
Royce & Associates LP860KShares$5.74 Million0.05% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL760KShares$5.07 Million0.01% of portfolio
-
Timelo Investment Management Inc.604KShares$4.03 Million1.17% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9501KShares$3.34 Million1.45% of portfolio
-
Royal Bank Of Canada Toronto, A6486KShares$3.24 Million0.0% of portfolio
-
Ring Mountain Capital, LLC Tiburon, CA395KShares$2.63 Million1.07% of portfolio
Latest Institutional Activity in PROF
Top Purchases
Top Sells
About PROF
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Insider Transactions at PROF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2025
|
Arun Swarup Menawat CEO |
BUY
Open market or private purchase
|
Direct |
12,027
+2.01%
|
$48,108
$4.73 P/Share
|
|
May 15
2025
|
Arun Swarup Menawat CEO |
BUY
Open market or private purchase
|
Direct |
10,003
+1.71%
|
$40,012
$4.33 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 22K shares |
|---|